Đang chuẩn bị liên kết để tải về tài liệu:
Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Our previous study suggested that the recurrent CHEK2 H371Y mutation is a novel pathogenic mutation that confers an increased risk of breast cancer. The purpose of this study was to investigate whether breast cancer patients with CHEK2 H371Y mutation were more likely to respond to neoadjuvant chemotherapy. |